Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of dovitinib in first-line advanced adrenocortical carcinoma
2011-002873-47Phase 2Terminated
- Sponsor
- SOGUG
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in adrenal cancer (ACC), sponsored by SOGUG. Primary endpoint: Overall response rate. Started Oct 2011; status: terminated.
02
Drugs
dovitinib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2011-002873-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002873-47.